×
Search your requirement
Search your requirement
Home
Press Releases
Submit Release
Events
Reach Us
Social media
Search
Home
Press Releases
Submit Release
Events
Reach Us
Search
MilliporeSigma receives the industry's first EXCiPACT certification for cell culture media manufacturing
Ibex Medical Analytics achieves notable milestones with its AI-first approach to cancer diagnostics
Albertsons Companies pharmacies now offer COVID and flu vaccines to help protect communities this respiratory virus season
OmniSYS rebrands as XiFin Pharmacy Solutions, launches Pharmacy Payor Rate Transparency Monitor, and earns the Pharmacy 500 Award
Gilead’s Livdelzi (Seladelpar) receives FDA accelerated approval for primary biliary cholangitis
ProJenX announces the formation of its Clinical Advisory Board
Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma
NewAmsterdam Pharma announces positive topline data from the Phase 3 BROOKLYN trial of Obicetrapib in heterozygous familial hypercholesterolemia patients
Cygnus Technologies and TriLink BioTechnologies® collaborate to launch AccuRes™ Host Cell DNA Quantification Kits
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.
Updated flu and COVID-19 vaccinations are now available at CVS Pharmacy® and MinuteClinic
FDA Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Relapsed or Refractory Follicular Lymphoma
Featured Press Releases
New EpiVax Study Uncovers the Role of Treg Epitopes (Tregitopes) in Antibody Maturation: Implications for Therapeutic Antibodies
Citius Pharmaceuticals' LYMPHIR™ wins FDA approval for relapsed/refractory cutaneous T-cell lymphoma
08 Aug 2024
Citius Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has
...
Study: BRENZAVVY® matches Dapagliflozin in Chinese type 2 diabetes
Neurotech Welcomes Industry Veteran Beth Marsh as Chief Commercial Officer
Haleon’s Otrivin® Brand Now Features Aptar’s First Nasal Pump Made with 52% Bio-based Material
Enhancing Preclinical Research Support, SoBran, Inc. Expands BioScience Services to Los Angeles
Matisse Pharmaceuticals receives INN for M6229, recognizing it as a first-in-class drug, isupartob sodium
By
Matisse Pharmaceuticals
Matisse Pharmaceuticals
15 Dec 2025
Sapio Sciences Collaborates with the Wellcome Sanger Institute on Transforming Digital Laboratories
By
Sapio Sciences
Sapio Sciences
11 Dec 2025
Medra Raises $52 Million in Series A Funding to Build Physical AI Scientists
By
Medra
Medra
11 Dec 2025
Voranigo® (vorasidenib) from Servier has received multiple regional Prix Galien Awards
By
Servier
Servier
09 Dec 2025
FIZE Medical, in an exclusive deal with Asahi Kasei Medical, has launched the FIZE kUO® System in Japan
By
FIZE Medical
FIZE Medical
09 Dec 2025
GMA with MOVIVA®: Setting New Standards in Endoscopic Bariatric Treatment.
By
Erbe Elektromedizin GmbH
Erbe Elektromedizin GmbH
03 Dec 2025
Log in
Username
Show
Remember Me
Log in
Create an account
Forgot your username?
Forgot your password?
Most Popular
ADARx doses first patient in Phase 3 STOP-HAE trial; ADX-324 receives orphan drug designation for hereditary angioedema
By
ADARx Pharmaceuticals
Oct 22
Fast Company recognizes Bruin Biometrics as a top 10 innovative medical device maker
By
Bruin Biometrics, LLC
Mar 25
At the Heart Failure Society of America, Bayer will showcase new data for KERENDIA® (finerenone)
By
Bayer
Sep 25
January
2026
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
User Area
Login page
Registration
Edit Profile
Forgot Password
Discover
About Us
Terms Of Use
Privacy Policy
FAQs
Engage with Us
Search on Site
Post Press Release
Promote Brand
List Your Event
Subscribe for e-Newsletter Monthly
Subscribe to the Pharmaceutical Era newsletter to receive timely updates from your favorite products.
Email
I consent to subscribing to the selected email lists.
Enter the code below
Subscribe
1
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. To find out more, please click
here
.
I understand